What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
Go back to What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1143.85 +28.15 (2.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1115.70 | 52 Week High | $88.16 | |||
| Open | $1142.20 | 52 Week Low | $67.88 | |||
| Day High | $1153.95 | P/E | 264.78 | |||
| Day Low | $1130.50 | EPS | $4.32 | |||
| Volume | 1,156,789 | |||||
